Percorrer por autor "Lambert, Jo L. W."
A mostrar 1 - 3 de 3
Resultados por página
Opções de ordenação
- Comparative in silico docking of bioactive peptides across the gut-skin axis: a systems approach to psoriasis modulation via the host-microbe interactionsPublication . Silva, Isa; Lambert, Jo L. W.; Pintado, Manuela; Coscueta, Ezequiel R.Introduction: Psoriasis and inflammatory bowel disease (IBD) are chronic immune-mediated disorders sharing epithelial barrier dysfunction, dysbiosis, and sustained pro-inflammatory signaling. The gut–skin axis represents a network of host–microbe interactions, where microbial metabolites and immune responses shape inflammation in both intestinal and cutaneous environments.1 Bioactive peptides (BPeps) from natural sources are promising immunomodulators that may restore barrier integrity and attenuate key pathways such as NF-?B, JAK/STAT, and MAPK.2 Given this complex interplay, molecular docking was applied as an in silico strategy to prioritize peptide–protein interactions for in vitro validation.
- Comparative in silico docking of bioactive peptides across the gut-skin axis: a systems approach to psoriasis modulation via the host-microbe interactionsPublication . Silva, Isa; Lambert, Jo L. W.; Pintado, Manuela; Coscueta, Ezequiel R.
- Interplay of bioactive peptides and the gut-skin axis: a novel perspective on psoriasis therapyPublication . Silva, Isa; Lambert, Jo L. W.; Pintado, Manuela; Coscueta, Ezequiel R.Psoriasis is a chronic immune-mediated inflammatory skin disease characterized by keratinocyte hyperproliferation and immune dysregulation, involving the activation of Th1/Th17 cells and elevated levels of cytokines such as TNF-α, IL-17, and IL-23. Although current treatments range from topical corticosteroids to systemic biologics, recent studies highlight the importance of the gut–skin axis in psoriasis pathogenesis, where gut dysbiosis and increased intestinal permeability contribute to systemic inflammation. This emerging link underscores the need for therapeutic strategies that address both gut and skin homeostasis. This PhD project hypothesizes that bioactive peptides (BPeps) derived from natural dietary sources can modulate inflammation and epithelial barrier integrity in both the gut and skin, offering a novel therapeutic avenue for psoriasis based on host–microbe interactions and personalised nutraceuticals. Selected using bioinformatics and machine learning tools, BPeps will be commercially synthesized and first screened in intestinal cell models to evaluate their immunomodulatory effects in gut dysbiosis and psoriasis. This includes profiling cytokine expression and analyzing NF-κB and JAK-STAT signaling pathways. Promising peptides will undergo simulated gastrointestinal digestion, and their colonic fractions will be tested in gut fermentation models to assess effects on microbiota composition, short-chain fatty acid production, and barrier function. Absorbed peptide fractions and microbiota-derived metabolites will then be applied to in vitro and ex vivo 3D psoriatic skin models to assess their influence on inflammation, tissue regeneration, and skin barrier restoration. In parallel, intact BPeps will be directly tested on psoriatic skin to evaluate local activity. This approach enables a comparative evaluation of peptide effects in both gut and skin systems as well as in the gut-skin axis. By bridging immunonutrition, microbiome science, and dermatology, this research contributes to advancing novel peptide-based therapies and deepening our understanding of host–microbe symbioses in chronic inflammatory diseases.